Navitoclax

Navitoclax is a drug that selectively binds to apoptosis suppressor proteins Bcl-2, Bcl-XL, and Bcl-w. These proteins are often overexpressed in various types of cancers, such as those of the lymph, breast, lung, prostate, and colon, and are associated with tumor drug resistance. By targeting these proteins, Navitoclax aims to promote cancer cell death and overcome resistance to other treatments, primarily benefiting patients with resistant forms of cancer.

Navitoclax was discovered on February 25th 2022 and it currently has a search volume of 1.9K with a growth of +245%.